|
Non-alcoholic Fatty Liver Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In obese and overweight children, regression analysis indicated that higher BMI and higher gamma-glutamyl transferase (γ-GT), triglycerides (TG), and FGF-21 levels were independent risk factors strongly correlated with NAFLD scores.
|
31750276 |
2019 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
We found that among the six biomarkers, only serum FGF21 was independently associated with intrahepatic triglyceride content (IHTC, standardized β = 0.185, P < 0.001) and was an independent risk factor for mild NAFLD.
|
31776449 |
2019 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Together, our studies identify an important role and regulation mechanism of TWIST2 in maintaining hepatic homeostasis by ameliorating steatosis, inflammation, and oxidative stress <i>via</i> the NF-κB-FGF21 or SREBP1c-FGF21 pathway, which may provide a new therapeutic scheme for nonalcoholic fatty liver disease.-Zhou, L., Li, Q., Chen, A., Liu, N., Chen, N., Chen, X., Zhu, L., Xia, B., Gong, Y., Chen, X. KLF15-activating Twist2 ameliorated hepatic steatosis by inhibiting inflammation and improving mitochondrial dysfunction <i>via</i> NF-κB-FGF21 or SREBP1c-FGF21 pathway.
|
31648561 |
2019 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The mechanisms by which FGF21 affects the pathogenesis of NAFLD would also be proposed for the further understanding of FGF21.
|
31419414 |
2019 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Only FGF-21 level was significantly higher in NAFLD children than in obese patients without NAFLD.
|
30921653 |
2019 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
This review appraises preclinical data to outline the current understanding of FGF21 function in both normal hepatic function and NAFLD.
|
31672443 |
2019 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
FGF21 expression was robustly increased after 5-weeks of feeding and significantly decreased after 12-weeks of feeding in fructose-induced NAFLD mice.
|
31668386 |
2019 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Overall, the findings of this study demonstrate that p.o. administration of HRI activators, by increasing FGF21, is a promising strategy for the treatment of type 2 diabetes mellitus and non-alcoholic fatty liver disease.
|
30927369 |
2019 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Amelioration of NAFLD in adipoWT mice promoted by pioglitazone was associated with up-regulation of Pparg, Fgf21 and down-regulation of Pepck liver expression.
|
31176759 |
2019 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adipokines such as fibroblast growth factor 21 (FGF21) and adipocyte fatty acid-binding protein (AFABP) have been associated with non-alcoholic fatty liver disease.
|
30912255 |
2019 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Plasma FGF21 was higher in patients with NASH (453 ± 262 pg/mL) when compared with the No NASH (341 ± 198 pg/mL, P = 0.03) or No NAFLD (325 ± 289 pg/mL, P = 0.02) groups.
|
30848827 |
2019 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hepatic regulation of VLDL receptor by PPARβ/δ and FGF21 modulates non-alcoholic fatty liver disease.
|
29289645 |
2018 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Fibroblast growth factor 21 (FGF21) plays an important role in liver metabolism and is also a potential marker for NAFL.
|
29753678 |
2018 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Dapagliflozin monotherapy reduced all measured hepatocyte injury biomarkers and FGF21, suggesting a disease-modifying effect in NAFLD.
|
29971527 |
2018 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Some new pharmacological strategies act broadly to alter energy balance or influence pathways that contribute to NAFLD (e.g., agonists for PPAR γ, PPAR α/δ, FXR and analogs for FGF-21, and GLP-1).
|
28867301 |
2018 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Hepatic regulation of VLDL receptor by PPARβ/δ and FGF21 modulates non-alcoholic fatty liver disease.
|
29289645 |
2018 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Complementary Role of Fibroblast Growth Factor 21 and Cytokeratin 18 in Monitoring the Different Stages of Nonalcoholic Fatty Liver Disease.
|
28698650 |
2017 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
CONCLUSIONS Sitagliptin can protect liver tissue and modulate lipid metabolism in NAFLD mice via elevating FGF-21 and FGF-19, upregulating liver PPAR-a and CREBH levels, and mediating expression levels of key enzymes for lipid metabolism.
|
28315901 |
2017 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The findings of the current study prove the protective role of taurine in NAFLD via a novel role in the amelioration of FGF-21/ SIRT1 axis, which could be considered a new therapeutic target.
|
28942443 |
2017 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
FGF21 is a novel biomarker for non-alcoholic fatty liver disease (NAFLD) in humans and limits hepatotoxicity in mice.
|
29107287 |
2017 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study was to evaluate hepatic FGF21 and omentin-1 mRNA expression as well as their serum levels as predictive markers of liver injury and insulin resistance in morbidly obese women with non-alcoholic fatty liver disease (NAFLD).
|
28820393 |
2017 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In summary, ChREBP and FGF21 constitute a signaling axis likely conserved in humans that mediates an essential adaptive response to fructose ingestion that may participate in the pathogenesis of NAFLD and liver fibrosis.
|
28123933 |
2017 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The purpose of this meta-analysis was to evaluate the diagnostic value of serum biomarkers including cytokeratin 18 (CK-18), fibroblast growth factor 21 (FGF-21), and combined biomarker panel (CBP) in the diagnosis of NAFLD, especially NASH.
|
28326329 |
2017 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Fibroblast Activation Protein Cleaves and Inactivates Fibroblast Growth Factor 21.
|
26797127 |
2016 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
An FGF21-PXR signaling pathway may be involved in decreased hepatic CYP3A4 metabolic activity in NAFLD.
|
27482056 |
2016 |